David Miller - Cipher Pharmaceuticals Director Fin
| CPHRFDelisted Stock | USD 2.57 0.00 0.00% |
Insider
David Miller is Director Fin of Cipher Pharmaceuticals
| Phone | 905 602 5840 |
| Web | https://www.cipherpharma.com |
David Miller Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Miller against Cipher Pharmaceuticals otc stock is an integral part of due diligence when investing in Cipher Pharmaceuticals. David Miller insider activity provides valuable insight into whether Cipher Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Cipher Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cipher Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Miller over two months ago Acquisition by David Miller of tradable shares of Murphy USA subject to Rule 16b-3 | ||
David Miller over six months ago Acquisition by David Miller of 3756 shares of Ellington Residential subject to Rule 16b-3 |
Cipher Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.149 % which means that it generated a profit of $0.149 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2403 %, meaning that it generated $0.2403 on every $100 dollars invested by stockholders. Cipher Pharmaceuticals' management efficiency ratios could be used to measure how well Cipher Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Cipher Pharmaceuticals has accumulated 507 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Cipher Pharmaceuticals has a current ratio of 2.46, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Cipher Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Cipher Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cipher Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cipher to invest in growth at high rates of return. When we think about Cipher Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Arjan Chima | Centr Brands Corp | 40 | |
| Dominic KingSmith | Crescita Therapeutics | N/A | |
| Arvind Utchanah | Knight Therapeutics | N/A | |
| BA BA | Knight Therapeutics | 53 | |
| Avi Krivorot | Cannara Biotech | N/A | |
| JD BA | HLS Therapeutics | 42 | |
| David Spence | HLS Therapeutics | 55 | |
| Anthony Manouk | Cannara Biotech | N/A | |
| France Landry | Cannara Biotech | N/A | |
| Alexander Wolfe | Cannara Biotech | N/A | |
| Arthur Danner | Centr Brands Corp | N/A | |
| Patricia Colvin | Bionoid Pharma | N/A | |
| Julia Bouvet | Cannara Biotech | N/A | |
| Jody Engel | Knight Therapeutics | N/A | |
| BA LLB | HLS Therapeutics | 65 | |
| Francois Lafortune | Crescita Therapeutics | N/A | |
| Etienne Ledoux | Cannara Biotech | N/A | |
| Joseph JD | Centr Brands Corp | 56 | |
| Sanjiv Sharma | HLS Therapeutics | 67 | |
| Daniela Marino | Knight Therapeutics | N/A | |
| Brian Sherman | Cannara Biotech | N/A | |
Management Performance
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 |
Cipher Pharmaceuticals Leadership Team
Elected by the shareholders, the Cipher Pharmaceuticals' board of directors comprises two types of representatives: Cipher Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cipher. The board's role is to monitor Cipher Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cipher Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cipher Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bryan Jacobs, Chief Officer | ||
| Craig Mull, Interim Chairman | ||
| Emilio Presti, Marketing Sales | ||
| Diane Gajewczyk, VP Affairs | ||
| Chuoru Li, Co Controller | ||
| David Miller, Director Fin |
Cipher Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cipher Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.45 % | ||||
| Operating Margin | 0.57 % | ||||
| Current Valuation | 46.13 M | ||||
| Shares Outstanding | 25.12 M | ||||
| Shares Owned By Insiders | 44.12 % | ||||
| Number Of Shares Shorted | 11.43 K | ||||
| Price To Earning | 15.54 X | ||||
| Price To Book | 1.63 X |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Cipher OTC Stock
If you are still planning to invest in Cipher Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cipher Pharmaceuticals' history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |